Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata
- PMID: 15761418
- DOI: 10.1016/j.jaad.2004.08.051
Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata
Abstract
Multiple cutaneous and uterine leiomyomata syndrome (MCL) is an autosomal dominant disease characterized by the presence of concurrent benign tumors of smooth muscle origin (leiomyoma) in the skin and uterus of affected females, and in the skin of affected males. MCL can also be associated with type II papillary renal cell cancer (HLRCC). The genetic locus for MCL and HLRCC was recently mapped to chromosome 1q42.3-43 and subsequently, dominantly inherited mutations in the fumarate hydratase gene ( FH ) were identified. Importantly, analysis of the FH gene in tumors of MCL patients revealed a second mutation inactivating the wild-type allele in some tumors. Based on these findings, it has been suggested that FH may function as a tumor suppressor gene in MCL. Here, we report the analysis of the FH gene in a group of 11 MCL families, with the identification of 8 different mutations accounting for the disease in all families. One of the mutations, 905-1G>A, has been identified in 4 families of Iranian origin. The analysis of highly polymorphic markers in the vicinity of the FH gene showed a shared haplotype in these 4 families, suggesting that 905-1G>A represents a founder mutation. Collectively, identification of 5 novel and 3 recurrent mutations further supports the role of FH in the pathogenesis of MCL.
Similar articles
-
Multiple cutaneous and uterine leiomyomata resulting from missense mutations in the fumarate hydratase gene.Clin Exp Dermatol. 2006 Jan;31(1):118-21. doi: 10.1111/j.1365-2230.2005.01977.x. Clin Exp Dermatol. 2006. PMID: 16309500
-
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.Nat Genet. 2002 Apr;30(4):406-10. doi: 10.1038/ng849. Epub 2002 Feb 25. Nat Genet. 2002. PMID: 11865300
-
Germline fumarate hydratase mutations in families with multiple cutaneous and uterine leiomyomata.J Invest Dermatol. 2003 Oct;121(4):741-4. doi: 10.1046/j.1523-1747.2003.12499.x. J Invest Dermatol. 2003. PMID: 14632190
-
Fumarate hydratase mutations and predisposition to cutaneous leiomyomas, uterine leiomyomas and renal cancer.Br J Dermatol. 2005 Jul;153(1):11-7. doi: 10.1111/j.1365-2133.2005.06678.x. Br J Dermatol. 2005. PMID: 16029320 Review.
-
Clinical and molecular genetic aspects of hereditary multiple cutaneous leiomyomatosis.Eur J Dermatol. 2009 Nov-Dec;19(6):545-51. doi: 10.1684/ejd.2009.0749. Epub 2009 Jul 10. Eur J Dermatol. 2009. PMID: 19939761 Review.
Cited by
-
Structural basis of fumarate hydratase deficiency.J Inherit Metab Dis. 2011 Jun;34(3):671-6. doi: 10.1007/s10545-011-9294-8. Epub 2011 Mar 29. J Inherit Metab Dis. 2011. PMID: 21445611 Free PMC article.
-
Multiple cutaneous and uterine leiomyomatosis syndrome: a review.J Clin Aesthet Dermatol. 2013 Apr;6(4):16-21. J Clin Aesthet Dermatol. 2013. PMID: 23630637 Free PMC article.
-
Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics.Fam Cancer. 2011 Jun;10(2):397-411. doi: 10.1007/s10689-011-9428-z. Fam Cancer. 2011. PMID: 21404119
-
Genetic and clinical characterization of a novel FH founder mutation in families with hereditary leiomyomatosis and renal cell cancer syndrome.Orphanet J Rare Dis. 2024 Jan 26;19(1):26. doi: 10.1186/s13023-024-03017-z. Orphanet J Rare Dis. 2024. PMID: 38279137 Free PMC article.
-
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome.Fam Cancer. 2010 Jun;9(2):245-51. doi: 10.1007/s10689-009-9312-2. Fam Cancer. 2010. PMID: 20091131
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous